U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22N4O2
Molecular Weight 374.4365
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OPK-88004

SMILES

CC(C)OC(=N[C@@]1([H])Cc2c3cc(ccc3n(Cc4ccccn4)c2C1)C#N)O

InChI

InChIKey=IHIWYQYVBNODSV-KRWDZBQOSA-N
InChI=1S/C22H22N4O2/c1-14(2)28-22(27)25-17-10-19-18-9-15(12-23)6-7-20(18)26(21(19)11-17)13-16-5-3-4-8-24-16/h3-9,14,17H,10-11,13H2,1-2H3,(H,25,27)/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H22N4O2
Molecular Weight 374.4365
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

LY2452473 is a selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activity. Upon oral administration, LY2452473 acts as an agonist in select tissues and organs, including skeletal muscle, bone and the penis, thereby binding to and activating androgen receptor (AR) while acting as an antagonist in the prostate, thereby blocking AR activation and AR-mediated cellular proliferation. This may improve muscle mass and strength, bone formation, and erectile dysfunction while not stimulating growth of the prostate. Eli Lilly was developing LY 2452473/tadalafil combination for the treatment of erectile dysfunction. In addition, Eli Lilly is studying the use of a targeted LY 2452473 therapy, as a possible improvement in quality of life for prostate cancer patients who have undergone radical prostatectomy.

Approval Year

PubMed

PubMed

TitleDatePubMed
Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans.
2012 Dec
Patents
Substance Class Chemical
Created
by admin
on Sat Jun 26 11:11:56 UTC 2021
Edited
by admin
on Sat Jun 26 11:11:56 UTC 2021
Record UNII
XKW9MYF94Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OPK-88004
Code English
(S)-(7-CYANO-4-((PYRIDIN-2-YL)METHYL)-1,2,3,4-TETRAHYDROCYCLOPENTA(B)INDOL-2-YL)CARBAMIC ACID ISOPROPYL ESTER
Common Name English
CARBAMIC ACID, N-((2S)-7-CYANO-1,2,3,4-TETRAHYDRO-4-(2-PYRIDINYLMETHYL)CYCLOPENT(B)INDOL-2-YL)-, 1-METHYLETHYL ESTER
Common Name English
TT-701
Code English
LY-2452473
Code English
LY2452473
Code English
Code System Code Type Description
PUBCHEM
24963749
Created by admin on Sat Jun 26 11:11:56 UTC 2021 , Edited by admin on Sat Jun 26 11:11:56 UTC 2021
PRIMARY
CAS
1029692-15-6
Created by admin on Sat Jun 26 11:11:56 UTC 2021 , Edited by admin on Sat Jun 26 11:11:56 UTC 2021
PRIMARY
ChEMBL
CHEMBL3542265
Created by admin on Sat Jun 26 11:11:56 UTC 2021 , Edited by admin on Sat Jun 26 11:11:56 UTC 2021
PRIMARY
FDA UNII
XKW9MYF94Y
Created by admin on Sat Jun 26 11:11:56 UTC 2021 , Edited by admin on Sat Jun 26 11:11:56 UTC 2021
PRIMARY
EPA CompTox
1029692-15-6
Created by admin on Sat Jun 26 11:11:56 UTC 2021 , Edited by admin on Sat Jun 26 11:11:56 UTC 2021
PRIMARY
DRUG BANK
DB12573
Created by admin on Sat Jun 26 11:11:56 UTC 2021 , Edited by admin on Sat Jun 26 11:11:56 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
After normalization for hepatic content of the contributing P450s, CYP3A4 was the largest contributor (68%) to substrate depletion, suggesting a major role of CYP3A4 in the hepatic clearance of LY2452473.
MAJOR
METABOLIC ENZYME -> SUBSTRATE
. CYP2J2 showed the second largest contribution to substrate depletion (15%) after normalization for hepatic content
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC